Toll Free: 1-888-928-9744

Alopecia - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alopecia - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Alopecia - Pipeline Review, H1 2016', provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Alopecia - The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects - The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Alopecia Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Alopecia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Alopecia Overview 11 Therapeutics Development 12 Pipeline Products for Alopecia - Overview 12 Pipeline Products for Alopecia - Comparative Analysis 13 Alopecia - Therapeutics under Development by Companies 14 Alopecia - Therapeutics under Investigation by Universities/Institutes 16 Alopecia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Alopecia - Products under Development by Companies 20 Alopecia - Products under Investigation by Universities/Institutes 23 Alopecia - Companies Involved in Therapeutics Development 24 Aclaris Therapeutics, Inc. 24 Allergan Plc 25 AndroScience Corporation 26 Berg LLC 27 BiologicsMD, Inc. 28 Bristol-Myers Squibb Company 29 Diffusion Pharmaceuticals LLC 30 Follicum AB 31 Histogen, Inc. 32 Hyundai Pharmaceutical Co., Ltd. 33 Incyte Corporation 34 Kuhnil Pharmaceutical Co., Ltd. 35 Lee's Pharmaceutical Holdings Limited 36 LEO Pharma A/S 37 NovaLead Pharma Pvt. Ltd. 38 Panacea Biotec Limited 39 Polichem S.A. 40 Quark Pharmaceuticals, Inc. 41 RepliCel Life Sciences, Inc. 42 RXi Pharmaceuticals Corporation 43 Sucampo Pharmaceuticals, Inc. 44 SWITCH Biotech LLC 45 Taisho Pharmaceutical Holdings Co., Ltd. 46 TetraLogic Pharmaceuticals 47 Tigo GmbH 48 Valeant Pharmaceuticals International, Inc. 49 Vida Therapeutics Inc. 50 Alopecia - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 54 Assessment by Route of Administration 56 Assessment by Molecule Type 58 Drug Profiles 60 A-201 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 A-301 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 abatacept - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Antibodies to Inhibit Heparanase for Cancer - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 ASCJ-9 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 bimatoprost - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 BMD-2341 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 BRM-421 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 calcitriol - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 CB-0301 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 DHL-HisZnNa - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 diphencyprone - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 finasteride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 finasteride - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 FOL-005 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 FS-2 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Hair Stimulating Complex - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 HTB-005 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 interferon beta-1b - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 KI-1104 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 KI-1105 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 LEO-124249 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 minoxidil - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 NLP-602 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 OLX-104 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 PRD-006 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 QPAL-1 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 QPAL-2 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 RCH-01 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 RES-440 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 RK-023 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 ruxolitinib phosphate - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 setipiprant - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 SHP-141 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 SM-04554 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Small Molecule for Androgenic Alopecia - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Synthetic Peptide for Alopecia - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 TASP-0382088 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 VTI-1000 Series - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 ZK-003 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 Alopecia - Recent Pipeline Updates 117 Alopecia - Dormant Projects 138 Alopecia - Discontinued Products 141 Alopecia - Product Development Milestones 142 Featured News & Press Releases 142 Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 142 Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 142 Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 143 Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 143 Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 144 Sep 04, 2014: FDA Approved Ruxolitinib Shown to Restore Hair Growth in Alopecia Patients 144 Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows 145 Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 145 Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia 145 Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB-03-01 146 Appendix 147 Methodology 147 Coverage 147 Secondary Research 147 Primary Research 147 Expert Panel Validation 147 Contact Us 147 Disclaimer 148
List of Tables
Number of Products under Development for Alopecia, H1 2016 12 Number of Products under Development for Alopecia - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Alopecia - Pipeline by Aclaris Therapeutics, Inc., H1 2016 24 Alopecia - Pipeline by Allergan Plc, H1 2016 25 Alopecia - Pipeline by AndroScience Corporation, H1 2016 26 Alopecia - Pipeline by Berg LLC, H1 2016 27 Alopecia - Pipeline by BiologicsMD, Inc., H1 2016 28 Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2016 29 Alopecia - Pipeline by Diffusion Pharmaceuticals LLC, H1 2016 30 Alopecia - Pipeline by Follicum AB, H1 2016 31 Alopecia - Pipeline by Histogen, Inc., H1 2016 32 Alopecia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 33 Alopecia - Pipeline by Incyte Corporation, H1 2016 34 Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2016 35 Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 36 Alopecia - Pipeline by LEO Pharma A/S, H1 2016 37 Alopecia - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 38 Alopecia - Pipeline by Panacea Biotec Limited, H1 2016 39 Alopecia - Pipeline by Polichem S.A., H1 2016 40 Alopecia - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 41 Alopecia - Pipeline by RepliCel Life Sciences, Inc., H1 2016 42 Alopecia - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 43 Alopecia - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 44 Alopecia - Pipeline by SWITCH Biotech LLC, H1 2016 45 Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 46 Alopecia - Pipeline by TetraLogic Pharmaceuticals, H1 2016 47 Alopecia - Pipeline by Tigo GmbH, H1 2016 48 Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 49 Alopecia - Pipeline by Vida Therapeutics Inc., H1 2016 50 Assessment by Monotherapy Products, H1 2016 51 Number of Products by Stage and Target, H1 2016 53 Number of Products by Stage and Mechanism of Action, H1 2016 55 Number of Products by Stage and Route of Administration, H1 2016 57 Number of Products by Stage and Molecule Type, H1 2016 59 Alopecia Therapeutics - Recent Pipeline Updates, H1 2016 117 Alopecia - Dormant Projects, H1 2016 138 Alopecia - Dormant Projects (Contd..1), H1 2016 139 Alopecia - Dormant Projects (Contd..2), H1 2016 140 Alopecia - Discontinued Products, H1 2016 141



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify